Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 40,813 followers.

https://t.co/c8e0WWU3V8

06 Feb 2024

Reply Repost Favourite

RT @FrontOncology: New research: Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lu…

11 Oct 2023

Reply Repost Favourite

New research: Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report: RET fusions occur in 1–2% of non-small cell… #oncology h

11 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.